Atea Pharmaceuticals Inc. (AVIR): Price and Financial Metrics

Atea Pharmaceuticals Inc. (AVIR): $4.60

0.03 (+0.66%)

POWR Rating

Component Grades













Add AVIR to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where AVIR ranks best; there it ranks ahead of 85.04% of US stocks.
  • AVIR's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • AVIR's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).

AVIR Stock Summary

  • AVIR's went public 2.24 years ago, making it older than just 10.45% of listed US stocks we're tracking.
  • For AVIR, its debt to operating expenses ratio is greater than that reported by only 6.89% of US equities we're observing.
  • AVIR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 7.04% of US stocks.
  • Stocks that are quantitatively similar to AVIR, based on their financial statements, market capitalization, and price volatility, are ARWR, ALLO, TSP, INDI, and EFTR.
  • Visit AVIR's SEC page to see the company's official filings. To visit the company's web site, go to

AVIR Valuation Summary

  • AVIR's EV/EBIT ratio is 6.5; this is 34.34% lower than that of the median Healthcare stock.
  • AVIR's EV/EBIT ratio has moved up 169.6 over the prior 27 months.

Below are key valuation metrics over time for AVIR.

Stock Date P/S P/B P/E EV/EBIT
AVIR 2023-01-20 2.1 0.6 11.4 6.5
AVIR 2023-01-19 2.1 0.6 11.3 6.4
AVIR 2023-01-18 2.0 0.6 11.0 6.1
AVIR 2023-01-17 2.1 0.6 11.5 6.6
AVIR 2023-01-13 2.1 0.6 11.5 6.6
AVIR 2023-01-12 2.1 0.6 11.4 6.5

AVIR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AVIR has a Quality Grade of C, ranking ahead of 64.7% of graded US stocks.
  • AVIR's asset turnover comes in at 0.261 -- ranking 171st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AVIR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.261 1 -0.219
2020-12-31 0.110 1 0.072

AVIR Price Target

For more insight on analysts targets of AVIR, see our AVIR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $49.00 Average Broker Recommendation 1.3 (Strong Buy)

AVIR Stock Price Chart Interactive Chart >

Price chart for AVIR

AVIR Price/Volume Stats

Current price $4.60 52-week high $9.79
Prev. close $4.57 52-week low $4.18
Day low $4.53 Volume 292,500
Day high $4.64 Avg. volume 349,611
50-day MA $4.66 Dividend yield N/A
200-day MA $6.35 Market Cap 383.12M

Atea Pharmaceuticals Inc. (AVIR) Company Bio

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

AVIR Latest News Stream

Event/Time News Detail
Loading, please wait...

AVIR Latest Social Stream

Loading social stream, please wait...

View Full AVIR Social Stream

Latest AVIR News From Around the Web

Below are the latest news stories about ATEA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AVIR as an investment opportunity.

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination Trial of Bemnifosbuvir and Ruzasvir in Patients Infected with Hepatitis C Virus (HCV) with Initial Results Anticipated 4Q23 BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq:

Yahoo | January 9, 2023

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a business update at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. PT in San Francisco, CA.

GlobeNewswire | January 4, 2023

Boston biotech retools Covid drug to make 'next generation of Paxlovid'

Following a disappointing readout from a mid-stage trial, a Boston biotech is retooling a Covid-19 antiviral in the hopes that it could help especially high-risk patients.

Yahoo | December 16, 2022

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status

GlobeNewswire | November 29, 2022

Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, together with other members of the Atea management team, will participate in a fireside chat and present a business update at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29 at 9:40 a.m. ET. A live webcast of the presentation

Yahoo | November 22, 2022

Read More 'AVIR' Stories Here

AVIR Price Returns

1-mo 5.75%
3-mo -22.03%
6-mo -43.90%
1-year -28.46%
3-year N/A
5-year N/A
YTD -4.37%
2022 -46.20%
2021 -78.60%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6521 seconds.